HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.

Abstract
Long-term safety and efficacy of once-daily ropinirole prolonged release (PR) were evaluated in subjects with early Parkinson's disease (PD). Subjects (n = 83) who completed one of two studies were enrolled in this open-label, multicenter, extension study, and followed for up to 78 months. Ropinirole PR was titrated/continued, and adjusted as appropriate during the maintenance phase (maximum 24 mg/day). L-dopa and other non-dopamine agonist PD medications were permitted. Safety outcomes included adverse events (AEs). Efficacy outcomes included Unified Parkinson's Disease Rating Scale (UPDRS) II and III scores, and Clinical Global Impression-Severity (CGI-S) and Improvement (CGI-I) scores. The median duration of ropinirole PR exposure was 1,069 days. Most subjects (97.6%) reported at least one AE, most commonly (≥ 30%) nausea (42.2%), dizziness (41.0%), peripheral edema (38.6%), back pain (33.7%), and headache (31.3%). Seventeen (20.5%) subjects discontinued due to an AE. UPDRS and CGI scores indicated that the clinical status of subjects was maintained throughout the treatment period. In patients with early PD, long-term treatment with once-daily ropinirole PR was not associated with any new safety concerns, and was effective in maintaining clinical status. These results support the extended use of ropinirole PR for treatment of PD.
AuthorsRobert A Hauser, Heinz Reichmann, Mark Lew, Afsaneh Asgharian, Clare Makumi, Kenneth J Shulman
JournalThe International journal of neuroscience (Int J Neurosci) Vol. 121 Issue 5 Pg. 246-53 (May 2011) ISSN: 1563-5279 [Electronic] England
PMID21244307 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Delayed-Action Preparations
  • Dopamine Agonists
  • Indoles
  • ropinirole
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Cross-Over Studies
  • Delayed-Action Preparations (administration & dosage, adverse effects)
  • Dopamine Agonists (administration & dosage, adverse effects)
  • Drug Administration Schedule
  • Female
  • Humans
  • Indoles (administration & dosage, adverse effects)
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy)
  • Severity of Illness Index
  • Time

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD